For instance, FAM129A, GMIP and NEK3 are altered in 107 (12%), 93 (10%) and 53 (6%) BRCA (breast cancer) tumours, respectively; ABT1 and SLC22A24 are altered in 19.6 and 14% of ACC (adrenocortical carcinoma) tumours; and ALPK2 and DPYSL2 are altered by frameshift MSI in 73 (17%) and 59 (14%) OV (ovarian serous cystadenocarcinoma) patients, respectively, but only in 62 of the remaining samples. Here, ALPK2 is linked to neoplasm.